Moreover, the IMPOWER 150 trial demonstrated that anti-PD-L1 agents, when combined with bevacizumab and platinum-based chemotherapy, can enhance the prognosis of advanced NSCLC (26). This evidence concerns the gene CD274 and non-small cell lung carcinoma.